Initial Importer Definition and Duties under 21 CFR 807.3(g)

1. Key takeaways

Under 21 CFR 807.3(g), an Initial Importer is an importer who furthers the marketing of a device from a foreign manufacturer to the final place of delivery or sale to the ultimate consumer or user, but who does not repackage or otherwise change the container, wrapper, or labeling of the device or packaging of the device. The Initial Importer carries four obligations: establishment registration, medical device reporting (21 CFR 803), correction and removal reporting (21 CFR 806), and device tracking (21 CFR 821, where applicable). The definition is narrow in one respect and broad in another: it depends entirely on whether the importer changes the packaging or labeling, and many importers perform that action without realizing that it changes their legal character and their duty set at the same time.

• Repackaging or relabeling converts the importer from an Initial Importer into a repacker or relabeler under the 21 CFR Part 807 subject list, changing the obligation structure.
• The importer is an independent MDR reporter, not merely a relay for the manufacturer, and must maintain an MDR event file for each adverse event.
• All product complaints, MDR and non-MDR events alike, must be forwarded to the manufacturer.
• The Initial Importer and the US Agent are two distinct roles, often confused; one company may hold both, but the roles must be recorded separately.
• Tracking obligations under 21 CFR 821 apply only where the device belongs to a tracked class, and require distribution-chain records.

2. Legal basis

The authorities below define the role and enumerate its duties. The importer provisions of 21 CFR 803.40 sit within the MDR regulation and are cited here because they are the operative text for the importer’s reporting behavior, while the FDA import guidance consolidates the four duties and the complaint-forwarding rule in one place.

3. Expert insights

Insight one: the condition of not changing the container, wrapper, or labeling is a limit, and once it is crossed the importer becomes a repacker or relabeler.

Under 21 CFR 807.3(g), the moment an importer repackages or alters the labeling, the Initial Importer definition no longer applies, and the firm falls into the category of repackers and relabelers within the 21 CFR Part 807 subject list, with a corresponding change in the obligation structure. This is the most common role misjudgment in practice. Importers add local-language inserts, swap outer cartons for retail packaging, or consolidate shipments into new boxes for distribution, and each of those acts crosses the line. The consequence is not merely academic: the new role brings its own registration content, its own inspection expectations, and its own records, and discovering the recharacterization during an inspection is far more disruptive than planning for it at contract stage.

Insight two: the importer is an independent MDR reporting subject, not a relay for the manufacturer.

FDA’s official pages make clear that under the MDR regulation, importers must report events in which a device may have caused or contributed to a death or serious injury, as well as certain malfunctions. The importer must maintain an MDR event file for each adverse event, and all product complaints, both MDR and non-MDR events, must be forwarded to the manufacturer. The two duties operate together but are distinct: filing is the importer’s own legal act on its own clock, while forwarding is the transmission duty that keeps the manufacturer’s program informed. An importer that treats complaint handling as optional courtesy to the brand owner is out of compliance even if the manufacturer learns of every event through other channels.

Insight three: the Initial Importer and the US Agent are two roles that are often conflated.

The US Agent is the communication channel for the foreign manufacturing establishment (21 CFR 807.40), while the Initial Importer is an import entity that bears its own statutory registration and reporting obligations (21 CFR 807.3(g)). A single company may serve in both capacities at once, but the legal roles must be recorded separately, because their duties, their definitions, and their regulatory anchors differ entirely. Blending them in one line of a registration form or a contract obscures which entity owes which duty, and it creates exactly the kind of ambiguity that becomes expensive to resolve when an adverse event or an inspection forces the question.

Insight four: a cross-market comparison of role names (practical estimate).

The United States uses the paired roles of US Agent plus Initial Importer; the European Union uses the Authorised Representative (EC REP); the United Kingdom uses the UK Responsible Person (UKRP); Thailand and Indonesia use local license holders or import license holders. The same enterprise carries different role names and different duty scopes in different jurisdictions, and the American framework must not be applied mechanically to other markets. Building a one-page role map per jurisdiction, refreshed when regulations change, keeps multi-market programs legible and prevents the quiet importation of one region’s assumptions into another’s compliance file.

4. Practical recommendations

• Determine the role first: whether the operation repackages or changes labeling decides between Initial Importer and repacker or relabeler status, and the determination should be made before the import contract is signed.
• Establish an MDR event file directory, archive by event, and share it with the manufacturer so both sides work from the same record.
• Build a complaint-forwarding mechanism under which all complaints, including non-MDR complaints, are forwarded to the manufacturer, with forwarding records retained.
• For tracked devices, maintain distribution-chain records separately so that the tracking obligation can be met without reconstructing the chain retrospectively.

5. Verification checklist

• □ It has been determined whether the operation is an Initial Importer under 21 CFR 807.3(g).
• □ The operation’s own establishment registration has been completed.
• □ An MDR event file (one file per event) has been established.
• □ A mechanism and records for forwarding all complaints to the manufacturer are in place.
• □ It has been confirmed whether the devices handled fall within the tracked classes of 21 CFR 821.
• □ A 10 business day reporting process for corrections and removals under 21 CFR 806 has been established.

Regulatory information verified as of October 28, 2026.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, US Agent and local testing support for the United States market. Our team manages FDA establishment registration and listing, 510(k)/De Novo/PMA submissions, and supports post-market reporting obligations. Business enquiries: info@grzanglobal.com